Cargando…
Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594135/ https://www.ncbi.nlm.nih.gov/pubmed/30973202 http://dx.doi.org/10.1111/head.13514 |
_version_ | 1783430196580319232 |
---|---|
author | Rosen, Noah Pearlman, Eric Ruff, Dustin Day, Kathleen Nagy, Abraham Jim |
author_facet | Rosen, Noah Pearlman, Eric Ruff, Dustin Day, Kathleen Nagy, Abraham Jim |
author_sort | Rosen, Noah |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-6594135 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65941352019-07-10 Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine Rosen, Noah Pearlman, Eric Ruff, Dustin Day, Kathleen Nagy, Abraham Jim Headache Comments, Observations, and Rebuttals John Wiley and Sons Inc. 2019-04-11 2019-04 /pmc/articles/PMC6594135/ /pubmed/30973202 http://dx.doi.org/10.1111/head.13514 Text en © 2019 Eli Lilly & Co. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Comments, Observations, and Rebuttals Rosen, Noah Pearlman, Eric Ruff, Dustin Day, Kathleen Nagy, Abraham Jim Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine |
title | Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine |
title_full | Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine |
title_fullStr | Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine |
title_full_unstemmed | Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine |
title_short | Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine |
title_sort | response to misused and misleading: 100% response rate to galcanezumab in patients with episodic migraine |
topic | Comments, Observations, and Rebuttals |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594135/ https://www.ncbi.nlm.nih.gov/pubmed/30973202 http://dx.doi.org/10.1111/head.13514 |
work_keys_str_mv | AT rosennoah responsetomisusedandmisleading100responseratetogalcanezumabinpatientswithepisodicmigraine AT pearlmaneric responsetomisusedandmisleading100responseratetogalcanezumabinpatientswithepisodicmigraine AT ruffdustin responsetomisusedandmisleading100responseratetogalcanezumabinpatientswithepisodicmigraine AT daykathleen responsetomisusedandmisleading100responseratetogalcanezumabinpatientswithepisodicmigraine AT nagyabrahamjim responsetomisusedandmisleading100responseratetogalcanezumabinpatientswithepisodicmigraine |